


Benign Prostatic Hyperplasia Treatment Market is growing at a CAGR of 5.3% from 2024 to 2030 by Exactitude Consultancy

The Exactitude Consultancy Benign Prostatic Hyperplasia Treatment Market Report – Size, Trends, and Forecast 2024-2030

LUTON, BEDFORDSHIRE, UNITED KINGDOM, August 19, 2024 /EINPresswire.com/ -- An insightful market analysis report focusing on the Benign Prostatic Hyperplasia Treatment market has just been released by Exactitude Consultancy, serving as a valuable resource for both industry leaders and newcomers. This



comprehensive report offers a detailed exploration of the global [Benign Prostatic Hyperplasia Treatment](#) market and its sub segments, providing revenue forecasts and strategic insights that can drive business success in the coming years in Life Sciences Industry. The research spotlights on the latest market insights, current situation analysis with upcoming trends, and breakdown of



Rising prevalence of BPH and advancements in minimally invasive treatments are driving strong demand in the Benign Prostatic Hyperplasia (BPH) market.”
Exactitude Consultancy

the products and services. It covers information on profit models, competition spectrum, and associated vendor strategies illustrated by major players and market participants. The report comprises an in-depth analysis and comprehensive analysis about the future trends as well as developments of the market. Additionally, insights regarding possible opportunities present in the global Benign Prostatic Hyperplasia Treatment market would help stakeholders in implementing strategic business plans. Various factors that may drive the growth of the global market in the current scenario, as well as coming years,

have been discussed in detail.

0.00 00000000 00 0000 00 000 0.00 00000000 00 0000, 00 0 0000 00 0.0% 0000000 000
000000000 0000000.

000 0 0000000 0000000:

<https://exactitudeconsultancy.com/reports/6559/benign-prostatic-hyperplasia-treatment-market/#request-a-sample>

In addition to answering these critical questions, the report offers a forward-looking perspective, providing insights into the future trajectory of the Benign Prostatic Hyperplasia Treatment market. It equips decision-makers with the knowledge needed to navigate the market's evolution during the forecasted period effectively.

000 000 000 00000000 0000000000 00 000 0000000:

Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Limited.

0000000 00000000000000:

In April 2022, Teleflex announced the launch of the UroLift System in Japan for the treatment of benign prostatic hyperplasia (BPH). The FDA had cleared the usage of UroLift System for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).

In September 2018, Boston Scientific Corporation acquired Augmenix, the developer of SpaceOAR intended to reduce common and debilitating side effects for men who undergo prostate cancer radiotherapy

This Benign Prostatic Hyperplasia Treatment research report sheds light on the major market players who are thriving in the market. Track business strategy, financial status and upcoming products.

0000000 00000000000 00000000000000 0000000000 0000000 000000000000000 0000000000:

0000000 00000000000 00000000000000 0000000000 0000000 00 0000000000, 0000-0000, (000
00000000)

Drug Class

Minimally Invasive Surgeries

Laser Therapy

□□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□ □□ □□□ □□□□, □□□□-□□□□, (□□□□ □□□□□□□□)

Hospitals

Ambulatory Surgical Centres

Specialty Clinics

This report caters to a wide audience, from industry experts seeking insights into the dynamic Benign Prostatic Hyperplasia Treatment market to newcomers looking for guidance. Customization options are available to ensure the report's relevance to your specific needs.

□□□□□□ □□□□□□□□

□□□□□□: □□□□□□□□□□ □□□□□□□□□□ □□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□□□

Benign prostatic hyperplasia refers to the nonmalignant growth of prostate tissue and is a frequent cause of lower urinary tract symptoms among men. BPH is considered a normal part of male aging and is hormonally dependent on testosterone and dihydrotestosterone (DHT) production. Approximately 50% of men demonstrate histopathologic benign prostatic hyperplasia by age 60 and 90% by age 85. Approximately 30 million men worldwide and 14 million men in the US are said to have benign prostatic hyperplasia symptoms.

Data from the Health Insurance Review and Assessment (HIRA) agency in 2018 revealed that nearly 7,600,000 patients were diagnosed with benign prostatic hyperplasia in 2010, which increased by 1.2 million in 2017. This represents an annual increase of about 7% and a total increase of 58% from 2010.

□□□□□□□□□□□□: □□□□□□□□□□ □□□□□□□□ □□□□□□□□□□

The market for treatments for benign prostatic hyperplasia presents significant growth opportunities for generic drug manufacturers. Generic versions are now available since the majority of drugs used to treat benign prostatic hyperplasia—including Avodart, Cialis, and Jalyn—have had their patents revoked. In addition, there is a robust product pipeline in the market for treatments for benign prostatic hyperplasia due to increased demand for more efficacious treatment options.

□□□ □□□□□□ □□ □□□□□□ □□□□□□□□□□ □□□□ □□□□□□□□ □□□ □□□□□□□□, □□□□ □□□□□□, □□□□□□□□□□, □□□□□□□ □□□□□□, □□□ □□□□□□□ □□□□ □□ □□□□□□ □□□□□□□□□□, □□□□□□□□□□:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

□□□□ □□□□ □□□□□ □□□□ □□□□□□:

<https://exactitudeconsultancy.com/reports/6559/benign-prostatic-hyperplasia-treatment-market/>

□□□ □□□□□ □□□□ □□□□□□□□ □□□ □□□□□ □□□□□ □□ □□□ □□□□□□□ □□□□□□□ □□ □□□ □□□□□□□'□
□□□□□□ □□□ □□□□□□□□□□□□□□ □□ □□□□□□□□□ □□□□□□□□□□□□□:

Regions witnessing a rise in investments in supply chain networks.

Countries that have benefited from recent import and export policies.

Regions experiencing a decline in consumer demand due to economic and political upheavals.

Benign Prostatic Hyperplasia Treatment Markets expected to emerge in specific geographies.

Regions likely to lose market share due to pricing pressures.

Leading players expected to expand their footprints in the near future.

Sustainability trends impacting the logistics and supply chain dynamics in the Benign Prostatic Hyperplasia Treatment

Demographic and economic environments creating new demand in developing economies.

Changing government regulations and their impact on business strategies and practices.

□□□ □□□□□□□□□□ □□□□□□□□□□ □□ □□□□ □□□□□□:

What is the expected market size and growth rate during the forecast period?

What are the key factors propelling the Benign Prostatic Hyperplasia Treatment market?

What risks and challenges lie ahead in the market?

Who are the prominent players in the Benign Prostatic Hyperplasia Treatment market?

What trends are influencing market shares?

What are the primary findings from Porter's five forces model?

What global expansion opportunities are available for the Benign Prostatic Hyperplasia Treatment market?

□□□□ □□ □□□ □□□□□□□□ □□ □□□□ □□□□□□□?

A thorough review of the Benign Prostatic Hyperplasia Treatment Market, including regional markets.

Comprehensive coverage of all segments of the Market to assess trends, developments and market size forecasts till 2024-2030.

A thorough examination of deals involved in the Market including product portfolio, revenue, SWOT analysis and recent company advancements are examined in the company profile.

The growth matrix analyzes the product categories and geographic regions in which market companies should focus their efforts to invest, consolidate, expand and/or diversify.

□□□□□□□□ □□□□□□:

<https://exactitudeconsultancy.com/ko/reports/6559/benign-prostatic-hyperplasia-treatment-market/>

<https://exactitudeconsultancy.com/zh-CN/reports/6559/benign-prostatic-hyperplasia-treatment-market/>

<https://exactitudeconsultancy.com/ja/reports/6559/benign-prostatic-hyperplasia-treatment-market/>

<https://exactitudeconsultancy.com/fr/reports/6559/benign-prostatic-hyperplasia-treatment-market/>

<https://exactitudeconsultancy.com/de/reports/6559/benign-prostatic-hyperplasia-treatment-market/>

□□□□□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□□□ □□□ □□□□□□□:

20% free customization.

Five Countries can be added as per your choice.

Five Companies can add as per your choice.

Free customization up to 40 hours.

Post-sales support for 1 year from the date of delivery.

□□□ □□□□: <https://exactitudeconsultancy.com/primary-research/>

□□□□□ □□:

□□□□□□□□□□ □□□□□□□□□□ is a Market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you. So, whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

□□□□□ □□□□□□□ □□□□□□□: <https://bulletin.exactitudeconsultancy.com>

Irfan T

Exactitude Consultancy

+1 704-266-3234

[email us here](#)

Visit us on social media:

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/736488242>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.